Your browser doesn't support javascript.
loading
Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.
Lozano, Teresa; Villanueva, Lorea; Durántez, Maika; Gorraiz, Marta; Ruiz, Marta; Belsúe, Virginia; Riezu-Boj, José I; Hervás-Stubbs, Sandra; Oyarzábal, Julen; Bandukwala, Hozefa; Lourenço, Ana R; Coffer, Paul J; Sarobe, Pablo; Prieto, Jesús; Casares, Noelia; Lasarte, Juan J.
Afiliação
  • Lozano T; Gene Therapy and Hepatology Division, Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain;
  • Villanueva L; Gene Therapy and Hepatology Division, Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain;
  • Durántez M; Gene Therapy and Hepatology Division, Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain;
  • Gorraiz M; Gene Therapy and Hepatology Division, Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
  • Ruiz M; Gene Therapy and Hepatology Division, Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
  • Belsúe V; Gene Therapy and Hepatology Division, Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain;
  • Riezu-Boj JI; Gene Therapy and Hepatology Division, Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
  • Hervás-Stubbs S; Gene Therapy and Hepatology Division, Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
  • Oyarzábal J; Small Molecule Discovery Platform, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain;
  • Bandukwala H; Signaling and Gene Expression Division, La Jolla Institute for Allergy and Immunology, San Diego, CA 92037; and.
  • Lourenço AR; Department of Cell Biology, Center for Molecular Medicine, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
  • Coffer PJ; Department of Cell Biology, Center for Molecular Medicine, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
  • Sarobe P; Gene Therapy and Hepatology Division, Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
  • Prieto J; Gene Therapy and Hepatology Division, Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain;
  • Casares N; Gene Therapy and Hepatology Division, Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain; jjlasarte@unav.es ncasares@unav.es.
  • Lasarte JJ; Gene Therapy and Hepatology Division, Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain; jjlasarte@unav.es ncasares@unav.es.
J Immunol ; 195(7): 3180-9, 2015 Oct 01.
Article em En | MEDLINE | ID: mdl-26324768
ABSTRACT
Regulatory T cell (Treg) activity is modulated by a cooperative complex between the transcription factor NFAT and FOXP3, a lineage specification factor for Tregs. FOXP3/NFAT interaction is required to repress expression of IL-2, upregulate expression of the Treg markers CTLA4 and CD25, and confer suppressor function to Tregs. However, FOXP3 is expressed transiently in conventional CD4(+) T cells upon TCR stimulation and may lead to T cell hyporesponsiveness. We found that a short synthetic peptide able to inhibit FOXP3/NFAT interaction impaired suppressor activity of conventional Tregs in vitro. Specific inhibition of FOXP3/NFAT interaction with this inhibitory peptide revealed that FOXP3 downregulates NFAT-driven promoter activity of CD40L and IL-17. Inhibition of FOXP3/NFAT interaction upregulated CD40L expression on effector T cells and enhanced T cell proliferation and IL-2, IFN-γ, IL-6, or IL-17 production in response to TCR stimulation. The inhibitory peptide impaired effector T cell conversion into induced Tregs in the presence of TGF-ß. Moreover, in vivo peptide administration showed antitumor efficacy in mice bearing Hepa129 or TC1 tumor cells when combined with sorafenib or with an antitumor vaccine, respectively. Our results suggest that inhibition of NFAT/FOXP3 interaction might improve antitumor immunotherapies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfócitos T Reguladores / Interleucina-17 / Ligante de CD40 / Fatores de Transcrição Forkhead / Fatores de Transcrição NFATC Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfócitos T Reguladores / Interleucina-17 / Ligante de CD40 / Fatores de Transcrição Forkhead / Fatores de Transcrição NFATC Idioma: En Ano de publicação: 2015 Tipo de documento: Article